NasdaqGS:ALNA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. More Details


Snowflake Analysis

Fair value with imperfect balance sheet.

Share Price & News

How has Allena Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ALNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: ALNA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-8.3%

ALNA

-5.9%

US Biotechs

-3.4%

US Market


1 Year Return

-17.4%

ALNA

21.7%

US Biotechs

29.4%

US Market

Return vs Industry: ALNA underperformed the US Biotechs industry which returned 21.7% over the past year.

Return vs Market: ALNA underperformed the US Market which returned 29.4% over the past year.


Shareholder returns

ALNAIndustryMarket
7 Day-8.3%-5.9%-3.4%
30 Day-0.6%-7.0%0.6%
90 Day26.7%0.8%6.3%
1 Year-17.4%-17.4%23.5%21.7%32.2%29.4%
3 Year-76.4%-76.4%14.4%8.7%51.3%41.7%
5 Yearn/a51.4%40.3%119.6%95.2%

Long-Term Price Volatility Vs. Market

How volatile is Allena Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Allena Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALNA ($1.66) is trading below our estimate of fair value ($10.63)

Significantly Below Fair Value: ALNA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALNA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ALNA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ALNA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ALNA is good value based on its PB Ratio (3.5x) compared to the US Biotechs industry average (4.1x).


Next Steps

Future Growth

How is Allena Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-0.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ALNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ALNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALNA's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ALNA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ALNA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Allena Pharmaceuticals performed over the past 5 years?

-20.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALNA is currently unprofitable.

Growing Profit Margin: ALNA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ALNA is unprofitable, and losses have increased over the past 5 years at a rate of 20.3% per year.

Accelerating Growth: Unable to compare ALNA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).


Return on Equity

High ROE: ALNA has a negative Return on Equity (-186.73%), as it is currently unprofitable.


Next Steps

Financial Health

How is Allena Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ALNA's short term assets ($31.3M) exceed its short term liabilities ($3.9M).

Long Term Liabilities: ALNA's short term assets ($31.3M) exceed its long term liabilities ($9.9M).


Debt to Equity History and Analysis

Debt Level: ALNA's debt to equity ratio (54.2%) is considered high.

Reducing Debt: Insufficient data to determine if ALNA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ALNA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ALNA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.4% each year


Next Steps

Dividend

What is Allena Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALNA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALNA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Lou Brenner (50 yo)

2.08yrs

Tenure

US$2,980,634

Compensation

Dr. Louis Brenner, also known as Lou, M.D., M.B.A., serves as Chief Executive Officer at Allena Pharmaceuticals, Inc since February 1, 2019. He served as the Chief Operating Officer of Allena Pharmaceutica...


CEO Compensation Analysis

Compensation vs Market: Lou's total compensation ($USD2.98M) is above average for companies of similar size in the US market ($USD506.59K).

Compensation vs Earnings: Lou's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Alexey Margolin
Co-Founder & Chairman of the Board2.08yrsUS$787.97k1.61%
$ 1.3m
Louis Brenner
President2.08yrsUS$2.98m0.29%
$ 240.4k
Robert Gallotto
Co-Founder & Strategic Adviser5.92yrsno datano data
Richard Katz
CFO, Principal Financial Officer & Principal Accounting Officer0.17yrno datano data
Geoffrey Swire
Senior VP of Corporate Development0.33yrno datano data
Hugh Wight
Senior Vice President of Technical Operationsno datano datano data
Alicja Januszewicz
Vice President of People & Culture2.17yrsno datano data
David Clark
Chief Medical Officer0.25yrno datano data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Management: ALNA's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Alexey Margolin
Co-Founder & Chairman of the Board2.08yrsUS$787.97k1.61%
$ 1.3m
Louis Brenner
President2.08yrsUS$2.98m0.29%
$ 240.4k
James Topper
Independent Director9.5yrsUS$103.59k0%
$ 0
Gino Santini
Independent Lead Director2.08yrsUS$133.09k0.031%
$ 25.9k
Robert Alexander
Independent Director4.75yrsUS$101.09k0%
$ 0
Andrew A. Hack
Independent Director2.75yrsUS$108.59k0%
$ 0
Ann Miller
Independent Director0.42yrno datano data
Allene Diaz
Independent Director1.92yrsUS$161.24k0%
$ 0
Alexey Vinogradov
Board Observerno datano datano data

2.1yrs

Average Tenure

56yo

Average Age

Experienced Board: ALNA's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ALNA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 114.1%.


Top Shareholders

Company Information

Allena Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Allena Pharmaceuticals, Inc.
  • Ticker: ALNA
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$83.417m
  • Shares outstanding: 50.25m
  • Website: https://www.allenapharma.com

Number of Employees


Location

  • Allena Pharmaceuticals, Inc.
  • One Newton Executive Park
  • Suite 202
  • Newton
  • Massachusetts
  • 2462
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ALNANasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDNov 2017
0PJDB (Deutsche Boerse AG)YesCommon SharesDEEURNov 2017

Biography

Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic,...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/04 00:12
End of Day Share Price2021/03/03 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.